P04-15. Prevalence of Broadly Neutralizing Antibody Responses During Acute/Early HIV Infection

DSpace/Manakin Repository

P04-15. Prevalence of Broadly Neutralizing Antibody Responses During Acute/Early HIV Infection

Citable link to this page

. . . . . .

Title: P04-15. Prevalence of Broadly Neutralizing Antibody Responses During Acute/Early HIV Infection
Author: Mikell, I; Sather, D; Kalams, S; Stamatatos, L; Altfeld, Marcus

Note: Order does not necessarily reflect citation order of authors.

Citation: Mikell, I., D. Sather, S. Kalams, Marcus Altfeld, and L. Stamatatos. 2009. P04-15. Prevalence of broadly neutralizing antibody responses during acute/early HIV infection. Retrovirology 6(Suppl 3): P43.
Full Text & Related Files:
Abstract: Background: Determining how cross-reactive neutralizing antibody (NAb) responses develop during natural HIV-1 infection may provide key information to understand the role they play in controlling the infection and in disease progression. Here we investigated the frequency and breadth of broadly NAb responses during acute and early infection in a well controlled cohort, and attempted to characterize the factors associated with the development of such responses. Methods: The plasma of 38 clade B acutely-infected, antiretroviral-naive subjects from two cohorts was screened for breadth of neutralization against a panel of heterologous isolates in an Env pseudovirus neutralization assay. Clade A, B and C variants were chosen from reference panels of viruses, created to evaluate the NAb responses elicited during infection or immunization. Results: Our preliminary screening strategy demonstrated that broadly neutralizing antibodies can be detected in a third of the infected subjects. Breadth of neutralization can develop as early as one year during natural HIV infection, however the majority of breadth was observed at over two years post infection. Conclusion: Cross-reactive NAbs are developed more frequently during early infection than previously thought. The consequences of this 'early' development of cross-reactive NAbs on plasma viremia and disease progression are under investigation. The work described was supported by National Institute of Health grant number R01 AI047708-11.
Published Version: doi:10.1186/1742-4690-6-S3-P43
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767944/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:4774089

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters